Organoid’s Potential to Advance Low Dose Research
Paul Locke Paul Locke

Organoid’s Potential to Advance Low Dose Research

By Loza Taye | April 3rd, 2025

Organoids will have an increasingly important role in shaping our understanding of radiation biology and in the development of policies and medical practices concerning radiation exposure.”

Image by aislan13

Read More
The Utility of an Intra-Agency NAM Office
Paul Locke Paul Locke

The Utility of an Intra-Agency NAM Office

By Breanne Kincaid | January 10th, 2025

“…the FDA’s NAM office represents a strategic evolution in integrating innovative methodologies into regulatory science. While it complements ICCVAM’s mission, its intra-agency focus and regulatory authority position it to drive faster, more context-specific advancements in risk assessment.“

Read More
ICCVAM 2024 Public Forum Highlights
Paul Locke Paul Locke

ICCVAM 2024 Public Forum Highlights

By Loza Taye | June 13th, 2024

“The 2024 ICCVAM Public Forum highlighted progress and future directions in alternative testing methods and how that work is proceeding in federal agencies and some partners. The presentations and discussions underscored a shared commitment to reducing animal testing while improving regulatory science and maintaining rigorous safety standards.”

Read More